SCHEMBL232145

SCHEMBL232145

COC(=O)c1ccc2ccn(C)c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.56
ALDH1A1 P00352 3/20 0.56
HPGD P15428 3/20 0.56
HSD17B10 Q99714 2/20 0.56
POLB P06746 1/20 0.56
APOBEC3A P31941 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
APOBEC3G Q9HC16 1/20 0.56
LMNA P02545 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
CYP2A6 P11509 1/20 0.47
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30623233 1.00 KDM4E (0.56) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL108632 0.87 TUBB4A (0.59) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL29944244 0.87 TUBB4A (0.59) KDM4EALDH1A1HPGDHSD17B10POLB
Ethoxycarbonyl Group SCHEMBL28293256 0.87 KDM4E (0.48) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL28264562 0.85 CYP2A6 (0.46) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL27736579 0.83 KDM4E (0.56) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL4255360 0.83 CA12 (0.51) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL22489748 0.82 KDM4E (0.54) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL28068122 0.82 KDM4E (0.54) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL30308312 0.81 CYP2A6 (0.51) KDM4EALDH1A1HPGDHSD17B10CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104387407-A 6-methyl-6H-benzo[4, 5]thiophene[2, 3-b]indole and derivatives thereof as well as synthesis method of 6-methyl-6H-benzo[4, 5]thiophene[2, 3-b]indole and derivatives thereof UNIV XIANGTAN 2015-03-04 CN claimed
US-20250197407-A1 TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE 2025-06-19 US disclosed
US-20250122152-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-04-17 US disclosed
EP-4496630-A1 TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS Jazz Pharmaceuticals Ireland Limited (IE) 2025-01-29 EP disclosed
CN-116867768-A STING antagonists and uses thereof 上海齐鲁锐格医药研发有限公司 2023-10-10 CN disclosed
WO-2023180345-A1 TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2023-09-28 WO disclosed
US-11414435-B2 Beta-lactamase inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2022-08-16 US disclosed
CN-113564623-A Method for preparing isatin compound by electrochemically oxidizing N-substituted indole derivative 福建师范大学 2021-10-29 CN disclosed
CN-109328059-B Selective inhibitors of clinically important mutants of EGFR tyrosine kinase CS制药技术有限公司 2021-08-17 CN disclosed
CN-107108512-B Therapeutic compounds and uses thereof 基因泰克公司 2021-05-04 CN disclosed
US-5856517-A ANTIPROLIFERATIVE AGENTS USEFUL IN THE TREATMENT OF CANCER. HOFFMANN-LA ROCHE INC. (US) 1999-01-05 US disclosed
EP-0622356-B1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMA (JP) 1998-07-01 EP disclosed
EP-0539117-B1 Compounds useful as leukotriene antagonists LILLY CO ELI (GB) 1998-03-11 EP disclosed
WO-1998004552-A1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION F. HOFFMANN-LA ROCHE AG (CH) 1998-02-05 WO disclosed
CN-1136038-A Indoloylguanidine derivatives SUMITOMO PHARMACEUTICS K K (JP) 1996-11-20 CN disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed
CN-1106800-A Indoloylguanidine derivatives SUMITOMO PHARMA (JP) 1995-08-16 CN disclosed
US-5410061-A Leukotriene antagonist LILLY INDUSTRIES LIMITED (GB) 1995-04-25 US disclosed
EP-0622356-A1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1994-11-02 EP disclosed
EP-0539117-A1 Compounds useful as leukotriene antagonists LILLY INDUSTRIES LIMITED (GB) 1993-04-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122152-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT7 KDM4E 948/4885ALDH1A1 3555/4885HPGD 2178/4885
US-11414435-B2 Beta-lactamase inhibitors MGAM, GAA, LCT KDM4E 720/4885ALDH1A1 305/4885HPGD 657/4885
US-20250197407-A1 TRICYCLIC PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS SOS1, SOS2, SOST KDM4E 3752/4885ALDH1A1 3590/4885HPGD 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.